Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
08/12/2019
Sangamo Therapeutics, Inc, a genomic medicine company, and Pfizer, Inc, announced on December 07th updated [...]